Company intelligence / Profile preview

JiaRay Group

San Diego, California, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Other

Overview

The lead candidate JR8603 targets legumain and has entered a Phase 1 clinical trial for advanced malignant solid tumors. The study includes dose escalation to determine safety/tolerability and maximum tolerated dose; secondary objectives include efficacy and pharmacokinetics. Exploratory endpoints involve biomarker analysis including serum legumain levels. No published efficacy results yet.

Therapeutic areas: Oncology
Modalities: Peptide-drug conjugateSmall molecule
Industry: Biotech

Partnerships

Jiangsu Jiarui Biotechnology Co., Ltd.

Beyond the preview

Go deeper on JiaRay Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JiaRay Group.

Explore the full profile